Pitch Introduction
Diabexy Shark Tank India appearance marked a pivotal moment for diabetes management solutions in the country. Founders Lokendra Tomar and Nishu Tomar entered the tank with a powerful mission: to prevent India from becoming the diabetes capital of the world. Their presentation highlighted a harsh reality – while Indians claim to be vegetarian, they are essentially grainatarians, consuming excessive grains that spike blood sugar levels dramatically.
The duo introduced their company NutroActive and its flagship brand Diabexy, offering food products with glycemic loads up to 89% lower than conventional alternatives. With India facing a diabetes epidemic affecting nearly every household, their solution addressed a massive healthcare challenge through dietary intervention rather than pharmaceutical dependence.
Business Overview
Diabexy operates on a unique food-as-medicine philosophy, creating specialized food products that help manage blood sugar levels naturally. The company produces diabetic-friendly alternatives to daily staples including atta (flour), rice, and sugar substitutes that minimize glucose impact while maintaining taste and nutritional value.
The business addresses a critical market gap where diabetic patients struggle to find suitable food options that do not compromise their health. By focusing on glycemic load reduction rather than just calorie counting, Diabexy provides scientifically formulated products that allow diabetics to enjoy traditional Indian meals without dangerous blood sugar spikes.
| Company Details | Information |
|---|---|
| Brand Name | Diabexy (by NutroActive) |
| Founders | Lokendra Tomar & Nishu Tomar |
| Founded Year | 2016 |
| Industry | Food & Beverage (Therapeutic Nutrition) |
| Website | diabexy.com |
| Original Ask | ₹1.5 Crore for 1% Equity |
About Founder’s
Lokendra Tomar brings a unique pharmaceutical background to the food industry. Originally aspiring to become a doctor, he pursued pharmacy when medical school did not work out, eventually working with Sun Pharma where he gained deep insights into diabetes medications. His wife Nishu Tomar complements his expertise by handling digital marketing, website development, and brand operations.
Their journey began in the forests of Chhattisgarh where Lokendra’s father worked as a government employee teaching tribals farming techniques. Despite financial hardships that required borrowing from neighbors, Lokendra developed an insatiable appetite for learning, reading over 1,000 books on personal development and nutrition. This self-education revealed that many diseases could be managed through food rather than drugs, inspiring the pivot from pharmaceuticals to therapeutic nutrition.
- Pharmacist turned food entrepreneur
- Bootstrap founders with no external employees
- Self-taught digital marketing experts
- Transitioned from keto products to diabetic nutrition
- Manage entire operations as husband-wife duo
Shark’s and Founder’s QnA
Peyush Bansal: How are you controlling diabetes? This is a huge issue in India, so how did you gain this knowledge?
Lokendra Tomar: I wanted to become a doctor but failed, so I became a pharmacist instead. This gave me knowledge of both medicines and food. I mixed food and pharma to create a new industry where food itself has therapeutic value, allowing patients to get treatment through their diet rather than just drugs.
Peyush Bansal: Tell us about your history and family background.
Lokendra Tomar: My grandparents were farmers, and my father was a government employee posted in Chhattisgarh teaching tribals how to farm. We faced financial difficulties; I remember borrowing from neighbors. When I came to Delhi and saw the prosperity here, I realized that business could bring that kind of prosperity to life.
Peyush Bansal: Which pharmaceutical company did you work for?
Lokendra Tomar: I worked at Sun Pharma where I sold medicines, including diabetes drugs. There I received the book How to Win Friends and Influence People, which opened my eyes to personal development – something they never teach in school. I started reading three books a week and realized many diseases can be cured through food without drugs.
Anupam Mittal: Walk us through your sales journey year by year.
Lokendra Tomar: We started in 2016. In 2016-17 we did ₹65 Lakhs. Then we grew to ₹1.5 Crores, then ₹3.15 Crores, then ₹5.15 Crores, then ₹8.15 Crores, and last year we reached approximately ₹13 Crores.
Anupam Mittal: Are you taking home profit after salary?
Lokendra Tomar: Yes, we made profit last year. We manufacture ourselves, so our margins are structured as one-third manufacturing cost, one-third distribution cost including Amazon fees, and one-third remaining for taxes and profit.
Anupam Mittal: What is your repeat customer percentage?
Lokendra Tomar: On our own website, repeat customers constitute about 70%. I still personally read all customer feedback to understand their experiences.
Anupam Mittal: What is the split between your weight loss and diabetes products?
Lokendra Tomar: Last year it was 50-50, but currently 70% of our revenue comes from diabetes products. Our recent monthly sales run rate is around ₹1.1 Crores.
Anupam Mittal: Is your other business declining while this grows?
Lokendra Tomar: Yes, the keto diet trend is slowly fading, so we are focusing more on the diabetes segment which has more staying power.
Anupam Mittal: How many SKUs do you have for diabetes products?
Lokendra Tomar: We have 16 different diabetic products currently, though with variants it becomes more. Our atta product alone accounts for 40% of diabetes sales.
Aman Gupta: This tastes good, but what is your new theory of diabetes?
Lokendra Tomar: The current thought process has an error. We say diabetes once acquired stays for life, but that is not true. Diabetes can be reversed completely, just like fever goes away. Gravity can be reversed with these food products.
Anupam Mittal: What is your team size?
Lokendra Tomar: Currently it is just the two of us managing everything.
Anupam Mittal: What is your five-year vision?
Lokendra Tomar: We expect to achieve over ₹500 Crores turnover in five years. We are introducing new products including diabetic rice. Our atta costs around ₹500 per kilogram, positioning it as a premium therapeutic product.
Anupam Mittal: Aren’t you worried about competition since you have no patented formulation?
Lokendra Tomar: Competition comes whether you grow or not. We have the competence advantage because we started this category, and we are open to collaboration rather than just competition.
Aman Gupta: My intention is to tell you that you are doing great work because diabetes affects so many people. However, you are the business – your knowledge and execution are the company. You should keep this to yourself and not bring external investors. I am out, but good luck.
Vineeta Singh: Let me explain valuation rationally. Your growing business Diabexy has ₹10 Crore sales and approximately ₹1 Crore profit. At a 7-8 times multiple, that values it at ₹7-8 Crores. We are offering ₹1.5 Crore for 20% equity, which means each shark gets 5%. This represents a fair valuation for your current stage.
Lokendra Tomar: It feels like the valuation does not match our expectations, so we are sorry. We were ready to come down to ₹15 Crores valuation, but this difference is too large.
Anupam Mittal: You came here for investment or marketing? Both had intention, but the rate list did not match.
Key Stats & Financials
Diabexy demonstrated impressive bootstrapped growth trajectory over six years, transitioning from a small keto-focused startup to a specialized diabetic nutrition brand serving over 3.5 lakh customers. The financial structure reveals a lean operation with straightforward cost distribution and healthy profitability.
- Sales Growth: From ₹65 Lakhs (2016-17) to ₹13 Crores (2021-22)
- Current Run Rate: ₹1.1 Crores monthly revenue
- Profit Margins: Approximately 33% net after all costs
- Repeat Customer Rate: 70% on direct website sales
- Team Size: Zero employees, founder-only operation
| Financial Metric | Value |
|---|---|
| Original Ask | ₹1.5 Crore for 1% |
| Implied Valuation | ₹150 Crores |
| Annual Revenue | ₹13 Crores |
| Estimated Profit | ₹1 Crore+ |
| COGS Breakdown | 33% Manufacturing |
| Primary Channel | Amazon + Direct Website |
Business Potential and TAM
India currently holds the distinction of being the diabetes capital of the world with over 70 million diagnosed cases and millions more prediabetic. This creates a massive Total Addressable Market (TAM) for therapeutic food products. As awareness grows about managing diabetes through diet rather than just medication, the demand for low glycemic load foods is projected to explode.
The shift from reactive pharmaceutical management to proactive dietary management represents a paradigm shift in healthcare. With increasing health consciousness among urban Indians and rising disposable incomes, premium therapeutic nutrition products are moving from niche medical recommendations to mainstream dietary choices.
- 70+ million diabetic patients in India
- Growing health consciousness in tier-1 and tier-2 cities
- Increasing preference for natural management over synthetic drugs
- Rising middle class willing to pay premium for health products
Diabexy: Ideal Target Audience & Demographics
| Demographic | Details |
|---|---|
| Age Group | 35-65 years |
| Location | Metro and Tier-1 cities |
| Income Level | ₹10 Lakhs+ annual household |
| Health Status | Diagnosed diabetics, prediabetics |
| Psychographic | Health-conscious, educated |
| Buying Behavior | Online shoppers, brand loyal |
Marketing and Distribution Strategy
Diabexy employs a digital-first direct-to-consumer strategy that has evolved significantly since inception. Initially leveraging Amazon’s marketplace to gain visibility and traction, the company has successfully migrated 70% of repeat customers to their proprietary website, reducing dependency on third-party platforms and improving margins.
The founders’ unique approach of personally engaging with customer feedback creates strong community bonds and product loyalty. Their content strategy focuses on education about glycemic load and diabetes reversal, positioning the brand as a thought leader rather than just a product seller.
- Started with Amazon marketplace for initial traction
- Shifted to direct website for higher margins and customer data
- Content marketing focused on diabetes education
- Premium pricing strategy positioning as therapeutic not commodity
Diabexy Deal Outcome
Despite compelling numbers and a noble mission, Diabexy left without a deal due to an insurmountable valuation gap. The founders maintained their stance on a ₹150 Crore valuation (later willing to compromise at ₹15 Crores), while the Sharks collectively offered ₹1.5 Crore for 20% equity, implying a ₹7.5 Crore valuation.
| Deal Parameter | Details |
|---|---|
| Offer Amount | ₹1.5 Crore |
| Equity Offered | 20% (5% per shark) |
| Implied Valuation | ₹7.5 Crores |
| Final Decision | Deal Rejected |
| Sharks in Offer | Vineeta, Anupam, Aman, Peyush |
Diabexy Post-Show Update
Following their Shark Tank India appearance, Diabexy continued its bootstrapped growth trajectory, focusing on expanding their diabetic product portfolio. The company successfully launched diabetic rice and expanded their atta variants, maintaining their premium positioning in the therapeutic food market. Their direct-to-consumer platform saw increased traffic from the show’s visibility, though the founders maintained their lean, two-person operation model.
Business Analysis & Lessons
The Diabexy pitch illustrates the tension between founder vision and investor valuation. While the Sharks recognized the business potential and social impact, they viewed the ₹150 Crore ask as disconnected from current financial metrics. Aman Gupta’s advice highlighted a crucial consideration for knowledge-based businesses: when the founder IS the business, bringing external capital requires careful thought about scalability and succession.
The founders’ decision to reject the offer demonstrates confidence in their bootstrapped model and the belief that dilution at current valuations would not serve long-term interests. For entrepreneurs in the FMCG health space, this pitch underscores the importance of aligning valuation expectations with proven revenue multiples and market comparables.
- Valuation expectations must align with revenue multiples
- Founder-dependent businesses face unique scaling challenges
- Bootstrapping can be preferable to excessive dilution
- Category creation requires patient capital
Pitch Conclusion
Diabexy’s Shark Tank India journey represents the classic dilemma of high-potential niche businesses: balancing growth capital needs against valuation reality. While the deal did not materialize, the exposure validated their mission to combat diabetes through dietary intervention. For entrepreneurs watching this pitch, the key takeaway is that while vision drives startups, sustainable valuation ensures longevity. Diabexy continues serving its growing customer base, proving that sometimes the best deal is the one you do not take.